Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab-Reference-Cited by-同舟云学术

Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab

Published:2019-01-07 Issue:6 Volume:46 Page:e203-e204
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Komatsu‐Fujii Takayoshi¹^ORCID,Nomura Motoo²^ORCID,Otsuka Atsushi¹,Ishida Yoshihiro¹^ORCID,Doi Keitaro²,Matsumoto Shigemi²,Muto Manabu²,Kabashima Kenji¹

Affiliation:

1. Department of DermatologyKyoto University Graduate School of Medicine Kyoto Japan

2. Department of Therapeutic Oncology Kyoto University Graduate School of Medicine Kyoto Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.14763

Reference5 articles.

1. Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients

2. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

3. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

4. Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series;Medical Molecular Morphology;2024-01-30

2. Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib;Case Reports in Oncology;2023-09-22

3. A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations;Cancer Medicine;2023-07-05

4. Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma;Frontiers in Oncology;2022-11-30

5. Near complete remission of a locally advanced giant melanoma of the vulva following hypo‑fractionated radiotherapy and immune checkpoint inhibitors: A case report;Oncology Letters;2022-11-02